Analysis on complications after intravitreal injection of bevacizumab
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [16]
  • |
  • Related [20]
  • | | |
  • Comments
    Abstract:

    AIM: To observe and analyze on the incidence rate and causes of complications after anintravitreal injection of bevacizumab.

    METHODS: Totally, 207 cases(207 eyes)with wet age-related macular degeneration were selected randomly. All cases were treated with intravitreal injections of bevacizumab(1.5mg/0.06mL)and asked for chief complaints at 1 day, 1 week, 4, 12 weeks after operation, and also examined for routine visual acuity(best corrected visual acuity, BCVA), non-contact tonometer, slit lamp microscope and indirect ophthalmoscope etc.

    RESULTS: Among 207 cases(207 eyes), visual acuity improved efficiency was 90.8% 12 weeks after treatment, foreign body sensation was found in 7 cases(3.4%), eyelid skin pruritus in 1 case(0.5%), conjunctival congestion in 6 cases(2.9%), subconjunctival hemorrhage in 1 case(0.5%), post-operative intraocular pressure elevation in 2 cases(1.0%).

    CONCLUSION: The intravitreal injection of bevacizumab is effective with fewer complications. We propose to carry out a further randomized multicenter and larger-sample clinical research and further draw up the clinical application criterion of bevacizumab.

    Reference
    1 Age Related Eye Disease Study Research Group.A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss:AREDS Report no. 8.Arch Ophthalmol 2001; 119(10):1417-1436
    2 Rosenfeld PJ,Moshfeghi AA,Puliafito CA.Optical coherencetomography findings after an intravitreal injection of bevacizumab(Avastin)for neovascularization age-related macular degeneration.Ophthalmic Surg Lasers Imaging 2005; 36(4):331-335
    3 Luthra S,Narayanan R,Marques LE,et al.Evaluation of in vitro effects of bevaeizumab(Avastin)on retinal pigment epithelial, neurosensory retinal, and microvaseular endothelial cells.Retina 2006; 26: 512-518
    4 Feiner L,Barr EE,Shui YB,et al.Safety of intravitreal injection of bevacizumab in rabbit eyes.Retina 2006; 26(8):882-888
    5 Kim JH, Kim C, Kim JH,et al.Absence of intravitreal bevacizumab-induced neuronal toxicity in the retina. Neurotoxicology 2008; 29(6):1131-1135
    6 刘文杰,高磊,东长霞,等.玻璃体腔内注射Bevacizumab治疗年龄相关性黄斑变性.国际眼科杂志 2010; 10(3):540-543
    7 Falkenstein IA,Cheng L,Freeman WR.Changes of intraocular pressure after intravitreal injection ofbevacizumab(Avastin).Retina 2007; 27(8): 1044-1047
    8 Arevalo JF,Fromow-Guerra J,Sanchez JG,et al.Primary intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration Results of the Pan-American Collaborative Retina Study Group at12 mo00.0.nths follow-up.Retina 2008; 28(10): 1387-1394
    9 Fung AE,Rosenfeld PJ,Reichel E.The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide.Br J Ophthalmol 2006; 90(11):1344-1349
    10 Wu L,Martinez-Castellanos MA,Quiroz-Mercado H,et al.Twelve month safety of intravitreal injections of bevacizumab(Avastin):results of the Pan American Collaborative Retina Study Group(PACORES).Graefe's Arch Clin Exp Ophthalmol 2008; 246(1): 81-87
    11 Ronan SM,Yoganathan P,Chien FY.Retinal pigment epithelium tears after intravitreal injection of bevacizumab(Avastin)for neovascular age-related macular degeneration.Retina 2007; 27(5): 535-540
    12 Wong LJ,Desai RU,Jain A,et al.Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.Retina 2008; 28(8): 1151-1158
    13 Chan CK,Meyer CH,Gross JG.Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration.Retina 2007; 27(5): 541-551
    14 Shah CP,Hsu J,Garg SJ, et al. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006; 142(6): 1070-1071
    15刘晓娟.玻璃体腔注射bevacizumab的并发症.眼科研究2010; 28(6):571-574
    16 Ikuno Y,Sayanagi K,Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathologicalmyopia:One-year results.Am J Ophthalmol 2009; 147(1): 94-100
    Cited by
    Comments
    Comments
    分享到微博
    Submit
Get Citation

Cui-Wei Zhang, Jin-Song Mo, Xu-Yang Liu,/et al.Analysis on complications after intravitreal injection of bevacizumab. Guoji Yanke Zazhi( Int Eye Sci) 2013;13(8):1654-1656

Copy
Share
Article Metrics
  • Abstract:1519
  • PDF: 1338
  • HTML: 0
  • Cited by: 0
Publication History
  • Received:May 31,2013
  • Revised:July 22,2013
  • Online: July 29,2013